<DOC>
	<DOCNO>NCT01024231</DOCNO>
	<brief_summary>The purpose study determine safety tolerability treatment BMS-936558 ( MDX-1106 ) combination Ipilimumab ( BMS-734016 ) give time sequence regimen subject unresectable Stage III Stage IV malignant melanoma ( MEL )</brief_summary>
	<brief_title>Dose-escalation Study Combination BMS-936558 ( MDX-1106 ) Ipilimumab Subjects With Unresectable Stage III Stage IV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histologic diagnosis malignant melanoma ( MEL ) Measurable unresectable Stage III IV MEL ECOG performance status score 0 1 Life expectancy ≥4 month For enrolled amendment 5 later , tumor tissue ( archival recent acquisition ) must available For Cohorts 15 , subject may treat 3 prior systemic standard treatment metastatic melanoma include postincisional adjuvant therapy . Subjects may treatment naïve . All metastatic melanoma regardless primary site disease allow For Cohorts 67 , subject may treat 3 prior systemic standard treatment metastatic melanoma ; include postincisional adjuvant therapy . Specifically , subject must receive ≥3 dos Ipilimumab therapy last dose administer within 412 week initiation study treatment History severe hypersensitivity reaction mAbs Prior malignancy active within previous 2 year except localized cancer consider cured opinion investigator present low risk recurrence Active autoimmune disease history know suspect autoimmune disease History recently active diverticulitis symptomatic peptic ulcer disease history adrenal insufficiency Regular narcotic analgesia Active , untreated central nervous system metastasis For subject enrol Cohorts 15 , prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 antiCTLA4 antibody For subject enrol Cohorts 67 , prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 antibody Any nononcology vaccine therapy use prevention infectious disease Concomitant therapy anticancer therapy , concurrent medical condition require use immunosuppressive medication use investigational drug Positive test human immunodeficiency virus ( HIV ) , acquire immunodeficiency syndrome ( AIDS ) , hepatitis B , hepatitis C Subjects weigh ≥125 kg exclude Cohort 5 Subjects Cohorts 6 7 must receive Ipilimumab monotherapy immediately prior study entry , must receive Ipilimumab part clinical trial Subjects ocular melanoma exclude Cohort 8</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>